0.70
price down icon1.46%   -0.0104
 
loading
Schlusskurs vom Vortag:
$0.7104
Offen:
$0.7152
24-Stunden-Volumen:
731.84K
Relative Volume:
0.54
Marktkapitalisierung:
$84.83M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-93.61M
KGV:
-0.3318
EPS:
-2.11
Netto-Cashflow:
$-71.16M
1W Leistung:
-2.78%
1M Leistung:
-21.35%
6M Leistung:
-32.04%
1J Leistung:
-31.37%
1-Tages-Spanne:
Value
$0.6902
$0.7196
1-Wochen-Bereich:
Value
$0.6771
$0.7738
52-Wochen-Spanne:
Value
$0.561
$2.11

Immunic Inc Stock (IMUX) Company Profile

Name
Firmenname
Immunic Inc
Name
Telefon
(332) 255-9818
Name
Adresse
1200 AVENUE OF THE AMERICAS, NEW YORK
Name
Mitarbeiter
90
Name
Twitter
@ImmunicInc
Name
Nächster Verdiensttermin
2025-03-17
Name
Neueste SEC-Einreichungen
Name
IMUX's Discussions on Twitter

Vergleichen Sie IMUX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
IMUX
Immunic Inc
0.70 84.83M 0 -93.61M -71.16M -2.11
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
441.30 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
521.00 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.83 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
560.14 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
241.20 28.51B 3.81B -644.79M -669.77M -6.24

Immunic Inc Stock (IMUX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-03-25 Eingeleitet William Blair Outperform
2024-11-25 Eingeleitet H.C. Wainwright Buy
2024-09-09 Fortgesetzt Leerink Partners Outperform
2024-08-27 Eingeleitet B. Riley Securities Buy
2022-10-21 Herabstufung SVB Leerink Outperform → Mkt Perform
2022-09-19 Fortgesetzt H.C. Wainwright Buy
2021-04-15 Eingeleitet Aegis Capital Buy
2021-03-24 Eingeleitet JMP Securities Mkt Outperform
2020-10-02 Eingeleitet SVB Leerink Outperform
2020-08-26 Eingeleitet Piper Sandler Overweight
2020-08-07 Fortgesetzt ROTH Capital Buy
2020-07-20 Eingeleitet BMO Capital Markets Outperform
2020-06-05 Eingeleitet Wedbush Outperform
2020-05-11 Eingeleitet H.C. Wainwright Buy
2020-03-25 Eingeleitet ROTH Capital Buy
2019-07-11 Eingeleitet Chardan Capital Markets Buy
Alle ansehen

Immunic Inc Aktie (IMUX) Neueste Nachrichten

pulisher
Jun 17, 2025

Financial Metrics Check: Immunic Inc (IMUX)’s Ratios for Trailing Twelve Months - DWinneX

Jun 17, 2025
pulisher
Jun 11, 2025

Immunic, Inc. (NASDAQ:IMUX) Given Average Rating of “Buy” by Brokerages - Defense World

Jun 11, 2025
pulisher
Jun 09, 2025

Immunic Post-Readout: Reiterating Strong Buy As Big Drop Appears Unwarranted (NASDAQ:IMUX) - Seeking Alpha

Jun 09, 2025
pulisher
Jun 09, 2025

Millennium Management LLC Has $580,000 Stake in Immunic, Inc. (NASDAQ:IMUX) - Defense World

Jun 09, 2025
pulisher
Jun 07, 2025

Immunic completes Phase 3 multiple sclerosis trial enrollmentICYMI - Proactive financial news

Jun 07, 2025
pulisher
Jun 06, 2025

Immunic Therapeutics reaches major milestone with completion of ENSURE Trial Enrollment - Proactive financial news

Jun 06, 2025
pulisher
Jun 06, 2025

Immunic at Jefferies Conference: Promising MS Drug Insights By Investing.com - Investing.com South Africa

Jun 06, 2025
pulisher
Jun 05, 2025

Immunic at Jefferies Conference: Promising MS Drug Insights - Investing.com Australia

Jun 05, 2025
pulisher
Jun 05, 2025

Small cap wrap: Midnight Sun Mining, Standard Uranium, Immunic, ReconAfrica... - Proactive Investors

Jun 05, 2025
pulisher
Jun 05, 2025

Market movers: Tesla, Verint, PVH, Immunic... - Proactive financial news

Jun 05, 2025
pulisher
Jun 05, 2025

Immunic (IMUX) Receives Continued 'Buy' Rating from D. Boral Cap - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Immunic (IMUX) Receives Continued 'Buy' Rating from D. Boral Capital | IMUX Stock News - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Immunic completes patient enrollment in Phase 3 relapsing multiple sclerosis trials - Proactive financial news

Jun 05, 2025
pulisher
Jun 05, 2025

Immunic Completes Enrollment in 2 Phase 3 Studies in Relapsing Multiple Sclerosis - MarketScreener

Jun 05, 2025
pulisher
Jun 05, 2025

IMUX: Promising Results of Vidofludimus Calcium in Multiple Scle - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS - The Malaysian Reserve

Jun 05, 2025
pulisher
Jun 05, 2025

Immunic Announces Completion of Enrollment for Both Phase 3 ENSU - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

IMUX Completes Enrollment for Phase 3 Trials in Multiple Sclerosis | IMUX Stock News - GuruFocus

Jun 05, 2025
pulisher
Jun 04, 2025

Top Executives Make Bold Moves with Major Immunic Stock Purchases! - TipRanks

Jun 04, 2025
pulisher
Jun 04, 2025

Immunic Approves Equity Plan Amendment at Annual Meeting - TipRanks

Jun 04, 2025
pulisher
Jun 03, 2025

Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering | IMUX Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Immunic Announces Closing Of Oversubscribed $65 Million Underwritten Public Offering - marketscreener.com

Jun 03, 2025
pulisher
Jun 03, 2025

Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering - Longview News-Journal

Jun 03, 2025
pulisher
Jun 03, 2025

Immunic raises $65M in public offering to fund clinical trials - Proactive financial news

Jun 03, 2025
pulisher
Jun 02, 2025

Immunic to Participate in Investor, Scientific and Industry Conf - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Immunic to Participate in Investor, Scientific and Industry Conferences in June - The Malaysian Reserve

Jun 02, 2025
pulisher
Jun 02, 2025

Immunic releases June conference schedule - Proactive financial news

Jun 02, 2025
pulisher
May 30, 2025

Immunic Announces $65 Million Public Offering - TipRanks

May 30, 2025
pulisher
May 30, 2025

Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering - Eastern Progress

May 30, 2025
pulisher
May 30, 2025

Immunic Inc. prices $65 million public offering By Investing.com - Investing.com South Africa

May 30, 2025
pulisher
May 30, 2025

Immunic (NASDAQ:IMUX) Price Target Lowered to $10.00 at D. Boral Capital - Defense World

May 30, 2025
pulisher
May 29, 2025

Immunic (IMUX) Launches $65M Public Offering, Shares Drop - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Immunic Tumbles After Pricing $65 Million Offering of Warrants - marketscreener.com

May 29, 2025
pulisher
May 29, 2025

Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Un - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Small cap wrap: Fineqia, Synchronoss, Santacruz Silver, Immunic... - Proactive financial news

May 29, 2025
pulisher
May 29, 2025

Immunic (IMUX) Receives Target Price Adjustment from D. Boral Ca - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Immunic (IMUX) Receives Target Price Adjustment from D. Boral Capital | IMUX Stock News - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Immunic (IMUX) Faces Price Target Reduction Amid Stock Offering - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Immunic (IMUX) Faces Price Target Reduction Amid Stock Offering | IMUX Stock News - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Immunic (IMUX) Launches Public Offering with Warrant Options | I - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Immunic shares fall 12% after pricing of $65 million underwritten public offering to fund trials - Seeking Alpha

May 29, 2025
pulisher
May 29, 2025

Immunic to raise up to $65M in underwritten public offering - Proactive Investors

May 29, 2025
pulisher
May 29, 2025

Immunic (IMUX) Launches Public Offering with Warrant Options | IMUX Stock News - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Immunic Announces Pricing Of Oversubscribed $65 Million Underwritten Public Offering - marketscreener.com

May 29, 2025
pulisher
May 29, 2025

Immunic Inc. prices $65 million public offering - Investing.com

May 29, 2025
pulisher
May 29, 2025

Immunic, Inc. Announces Proposed Public Offering - Longview News-Journal

May 29, 2025
pulisher
May 28, 2025

Immunic launches public offering of warrants to fund clinical trials; shares down - MSN

May 28, 2025
pulisher
May 28, 2025

Immunic slides on planned equity raise - TradingView

May 28, 2025

Finanzdaten der Immunic Inc-Aktie (IMUX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Immunic Inc-Aktie (IMUX) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Tardio Jason
President and COO
Jun 05 '25
Buy
0.79
12,512
9,884
12,512
Vitt Daniel
CEO and Director
Jun 04 '25
Buy
0.77
15,000
11,550
29,000
Neermann Joerg
Director
Jun 04 '25
Buy
0.77
70,000
53,900
170,000
Neermann Joerg
Director
Jun 05 '25
Buy
0.76
30,000
22,800
200,000
Whaley Glenn
Chief Financial Officer
Jun 03 '25
Buy
0.71
45,000
32,076
95,510
Rudick Richard Alan
Director
Jun 03 '25
Buy
0.70
143,075
100,024
230,375
Rudick Richard Alan
Director
Nov 12 '24
Buy
1.15
87,300
100,369
87,300
$20.50
price down icon 1.11%
$35.87
price up icon 1.70%
$20.60
price down icon 3.38%
$99.49
price down icon 2.21%
$106.72
price up icon 0.55%
biotechnology ONC
$241.20
price down icon 5.22%
Kapitalisierung:     |  Volumen (24h):